Naureen Starling: Dostarlimab Offers New Hope for Patients with Locally Advanced Rectal Cancer

Coverage, in order

1. 4d ago
   
   OncoDaily obscure study n=68

   Naureen Starling: Dostarlimab Offers New Hope for Patients with Locally Advanced Rectal Cancer

   The Royal Marsden NHS Foundation Trust shared on LinkedIn: “68 per cent of patients with a type of locally advanced rectal cancer (LARC) remained cancer-free for at least 12 months after

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.